Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology
- New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology
- pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models
- John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours
London, UK – 16 March 2022 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today notes the publication of two studies in Cell Reports Medicine and Frontiers in Immunology co-authored by its Chief Scientific Officer John Maher.
